BioSpace News Archive

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its previously announced underwritten public offering of 14,000,000 shares of its common stock at a price to the public of $5.00 per share.

Hoth Therapeutics, Inc. (“Hoth” or the “Company”) (NASDAQ: HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,818,182 shares of common stock at a public offering price of $2.75 per share, before underwriting discounts and commissions.

Technavio has been monitoring the homecare ventilator market and it is poised to grow by USD 197.06 million during 2020-2024, progressing at a CAGR of over 7% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/new

Boston Scientific Corporation (NYSE: BSX) announced the pricing of concurrent offerings of 25,550,000 shares of its common stock (“Common Stock”) at a price to the public of $34.25 per share and 8,750,000 shares of its 5.50% Mandatory Convertible Preferred Stock, Series A

Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to PBGM01 broadly for the treatment of GM1 gangliosidosis. PBGM01 is an AAV-delivery gene therapy currently being developed for the treatment of infantile GM1 gangliosidosis (

OrthogenRx, Inc., a medical device company focused on the development and commercialization of treatments for knee pain caused by osteoarthritis (OA), today announced that “The Journal of Bone and Joint Surgery (JBJS)” has published a response in the journal’s Orthopaedic Forum,

In virtual meetings with lawmakers and on Twitter tomorrow, physician and health professional leaders from the American College of Rheumatology (ACR) are sounding the alarm about the economic impact of COVID-19 on rheumatology practices and the urgent need for more targeted relief that will help specialty practices remain solvent and continue to serve patients.

Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present and take meetings at upcoming virtual healthcare investor conferences in May and June 2020.

In an ongoing effort to help slow the spread of the virus, CVS Health expanded its COVID-19 testing program by announcing 16 additional test sites at select CVS Pharmacy drive-thru locations across Arizona.

Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing, today announced that it will present preclinical data of TST001, a humanized Claudin 18.2 (CLDN18.2) monoclonal antibody developed by its subsidiary Mabspace Biosciences,